KRAS and pancreatic adenocarcinoma: Correspondingly, HLA-A02+B62+B44−-related ‘indicator’ co-occurrence of KRAS G12D and TP53 mutations was verified to be significantly relevant to poor outcomes in stage I–II PAAD patients in both TCGA and ICGC cohort.